499769-91-4 Usage
Uses
Used in Pharmaceutical Industry:
1,3-Benzothiazol-6-ylboronic Acid, 97% is used as a reagent for the synthesis of various pharmaceuticals, contributing to the development of new drugs and therapeutic agents. Its role in palladium-catalyzed cross-coupling reactions allows for the creation of complex molecular structures that are essential in medicinal chemistry.
Used in Polymer Industry:
In the polymer industry, 1,3-Benzothiazol-6-ylboronic Acid, 97% is used as a precursor in the synthesis of specific types of polymers. Its involvement in cross-coupling reactions enables the formation of polymers with unique properties, such as improved strength, flexibility, or chemical resistance.
Used in Chemical Research and Development:
1,3-Benzothiazol-6-ylboronic Acid, 97% is utilized in the field of chemical research and development as a key compound for exploring new reaction pathways and understanding the mechanisms of organoboron chemistry. Its high purity level ensures that the results of these studies are reliable and accurate, facilitating advancements in the broader field of organic synthesis.
Check Digit Verification of cas no
The CAS Registry Mumber 499769-91-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,9,9,7,6 and 9 respectively; the second part has 2 digits, 9 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 499769-91:
(8*4)+(7*9)+(6*9)+(5*7)+(4*6)+(3*9)+(2*9)+(1*1)=254
254 % 10 = 4
So 499769-91-4 is a valid CAS Registry Number.
499769-91-4Relevant academic research and scientific papers
Enhanced treatment regimens using mTor inhibitors
-
Page/Page column 126, (2015/11/27)
The present invention provides for methods and pharmaceutical compositions comprising inhibitors of mTorC1 and/or mTorC2. In some aspects, the invention provides for treatment regimens resulting in enhanced treatment efficacy and better tolerability.
COMBINATION OF KINASE INHIBITORS AND USES THEREOF
-
Paragraph 00154, (2014/10/04)
The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth. The present invention also provides a pharmaceutical kit effective for treating a disease condition associated with PI3 -kinase α and/or mTOR in a subject.
COMBINATION PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
-
Paragraph 0498, (2014/12/09)
The present invention provides for methods and pharmaceutical compositions for treating proliferative disorders. In one aspect, the method comprises administration of two cell-cycle suppressors having a synergistic effect. In another aspect, two cell-cycle suppressors having a synergistic effect are provided in a pharmaceutical composition.
Xn:Harmful;
